Mien-Chie Hung received undergraduate and graduate degrees from National Taiwan University and his Ph.D. from Brandeis University. After completing postdoctoral training with Dr. Robert A. Weinberg at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, Dr. Hung was recruited to the University of Texas’s MD Anderson Cancer Center in 1986. There, until departing in February 2019 to become President of China Medical University in Taichung, Taiwan, he served from 2000 as Chairman of the Department of Molecular and Cellular Oncology and from 2010 as Vice President for Basic Research.
Dr. Hung’s research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. He is internationally recognized for his studies of signal transduction pathways regulated by tyrosine kinase growth factor receptors, such as EGFR and HER-2/neu, as well as molecular mechanisms of tumorigenesis.
Dr. Hung is a member of the Selection Committee for the Tang Prize in Biopharmaceutical Science category. He also serves as an editorial member for many journals in cancer research to evaluate quality of submissions. Notably, Dr. Hung is one of the founding Editorial Members for Cancer Cell and the American Journal for Cancer Research, where he continues to serve as Senior Editor. He was inducted as an academician into Taiwan’s Academia Sinica in 2002 and selected as a fellow of the American Association for the Advancement of Science in 2010. Dr. Hung has published no fewer than 480 peer-reviewed articles.
